Journal
JOURNAL OF NEUROCHEMISTRY
Volume 82, Issue 2, Pages 283-294Publisher
WILEY-BLACKWELL
DOI: 10.1046/j.1471-4159.2002.00970.x
Keywords
Alzheimer's disease; beta-amyloid precursor protein (APP); cytotoxic peptides; neurodegeneration; neuronal cell death; neurotoxicity
Categories
Funding
- NIA NIH HHS [AG05131] Funding Source: Medline
- NINDS NIH HHS [NS33376, NS35155] Funding Source: Medline
Ask authors/readers for more resources
The synapse loss and neuronal cell death characteristic of Alzheimer's disease (AD) are believed to result in large part from the neurotoxic effects of beta-amyloid peptide (Abeta), a 40-42 amino acid peptide(s) derived proteolytically from beta-amyloid precursor protein (APP). However, APP is also cleaved intracellularly to generate a second cytotoxic peptide, C31, and this cleavage event occurs in vivo as well as in vitro and preferentially in the brains of AD patients (Lu et al . 2000). Here we show that APPC31 is toxic to neurons in primary culture, and that like APP, the APP family members APLP1 and possibly APLP2 are cleaved by caspases at their C-termini. The carboxy-terminal peptide derived from caspase cleavage of APLP1 shows a degree of neurotoxicity comparable to APPC31. Our results suggest that even though APLP1 and APLP2 cannot generate Abeta, they may potentially contribute to the pathology of AD by generating peptide fragments whose toxicity is comparable to that of APPC31.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available